151 related articles for article (PubMed ID: 9592982)
41. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
42. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
43. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
[TBL] [Abstract][Full Text] [Related]
44. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
[TBL] [Abstract][Full Text] [Related]
45. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.
Carella AM; Carlier P; Pungolino E; Resegotti L; Liso V; Stasi R; Montillo M; Iacopino P; Mirto S; Pagano L
Leukemia; 1993 Feb; 7(2):196-9. PubMed ID: 8426473
[TBL] [Abstract][Full Text] [Related]
46. [Salvage combination chemotherapy with cytarabine, carboplatin and steroids for relapsed or refractory non-Hodgkin's lymphoma].
Yamamura R; Yamane T; Aoyama Y; Nakamae H; Hasegawa T; Ohta K; Nakao Y; Ohta T; Mugitani A; Hino M
Gan To Kagaku Ryoho; 2004 Mar; 31(3):373-5. PubMed ID: 15045943
[TBL] [Abstract][Full Text] [Related]
47. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
[TBL] [Abstract][Full Text] [Related]
48. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
Barone S; Baer MR; Sait SN; Lawrence D; Block AW; Wetzler M
Am J Hematol; 2001 Jun; 67(2):119-24. PubMed ID: 11343384
[TBL] [Abstract][Full Text] [Related]
49. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
50. Idarubicin combined with intermediate-dose cytosine arabinoside in the treatment of refractory acute leukemia.
Leone G; Pagano L; Marra R; Di Pietro N; Storti S; Sica S; D'Onofrio G; Ganzina F
Haematologica; 1989; 74(1):57-61. PubMed ID: 2498185
[TBL] [Abstract][Full Text] [Related]
51. [Response-oriented salvage chemotherapy with mitoxantrone, etoposide and enocitabine for previously treated acute myeloid leukemia. Tohoku Leukemia Study Group].
Chubachi A; Kuriya S; Narigasawa Y; Meguro K; Endo K; Takami H; Sato S; Sasaki H; Shiga T; Maruyama Y
Gan To Kagaku Ryoho; 1995 Dec; 22(14):2101-6. PubMed ID: 8607622
[TBL] [Abstract][Full Text] [Related]
52. FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphoma.
Zinzani PL; Bendandi M; Gherlinzoni F; Merla E; Gozzetti A; Tura S
Haematologica; 1996; 81(2):168-71. PubMed ID: 8641650
[TBL] [Abstract][Full Text] [Related]
53. Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma.
Case DC; Hayes DM; Gerber M; Gams R; Ervin TJ; Dorsk BM
Cancer Res; 1990 Nov; 50(21):6833-5. PubMed ID: 2208149
[TBL] [Abstract][Full Text] [Related]
54. [Early phase II study of Idarubicin combined with cytarabine in acute myelogenous leukemia. Idarubicin Study Group].
Ogawa M; Masaoka T; Yamada K; Kimura K
Gan To Kagaku Ryoho; 1993 May; 20(7):907-14. PubMed ID: 8489297
[TBL] [Abstract][Full Text] [Related]
55. Phase I-II trial of high dose Ara-C, carboplatinum, etoposide and steroids in patients with refractory or relapsed lymphomas.
Ahmed T; Cook P; Feldman E; Coombe N; Puccio C; Mittelman A; Chun H; Coleman M; Helson L
Leukemia; 1994 Apr; 8(4):531-4. PubMed ID: 8152247
[TBL] [Abstract][Full Text] [Related]
56. Idarubicin and high dose cytarabine: a new salvage treatment for refractory or relapsing non-Hodgkin's lymphoma.
Dufour P; Mors R; Berthaud P; Lamy T; Bergerat JP; Herbrecht R; Maloisel F; Audhuy B; Lioure B; Giron C; Hurteloup P; Oberling F
Leuk Lymphoma; 1996 Jul; 22(3-4):329-34. PubMed ID: 8819082
[TBL] [Abstract][Full Text] [Related]
57. [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia].
Esumi N; Todo S; Arakawa S; Imashuku S
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):951-8. PubMed ID: 3963859
[TBL] [Abstract][Full Text] [Related]
58. ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience.
Wang WS; Chiou TJ; Liu JH; Fan FS; Yen CC; Tung SL; Chen PM
Jpn J Clin Oncol; 1999 Jan; 29(1):33-7. PubMed ID: 10073149
[TBL] [Abstract][Full Text] [Related]
59. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
Lee JH; Lee KH; Kim S; Seol M; Kim SH; Kim WK; Lee JS
Leuk Res; 2001 Apr; 25(4):305-12. PubMed ID: 11248327
[TBL] [Abstract][Full Text] [Related]
60. [Vindesine, CCNU, high-dosage ara-C, and prednisolone (VINAP regimen) in the treatment of relapsing or refractory non-Hodgkin's lymphomas].
Domingo Albós A; Callís M; Juliá A; Vilá J; Zuazu J; Puig J; Petit J; Fernández-Sevilla A
Sangre (Barc); 1989 Apr; 34(2):107-11. PubMed ID: 2756450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
